Evidence map›Paper›PMID 35150316›Full record

ArticleMedical oncology (Northwood, London, England)2022

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma.

Hua Zhang, Jintong Chen, Mingyue Zhang, Munan Zhao, Luyao Zhang, Bin Liu, Siqing Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. New role for GCH1 in cancer.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hua ZhangDepartment of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, 130021, China.
Jintong ChenDepartment of Cancer Immunology, The First Hospital of Jilin University, 519 Dongminzhu St, Changchun, 130061, Jilin, China.
Mingyue ZhangDepartment of Gynecological Oncology, The First Hospital of Jilin University, Changchun, 130021, China.
Munan ZhaoDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Luyao ZhangDepartment of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, 130021, China.
Bin LiuDepartment of Hand and Foot Surgery, The First Hospital of Jilin University, 71 Xinmin St, Changchun, 130021, Jilin, China. l_bin@jlu.edu.cn.
Siqing WangDepartment of Cancer Immunology, The First Hospital of Jilin University, 519 Dongminzhu St, Changchun, 130061, Jilin, China. wkerger@jlu.edu.cn.ORCID http://orcid.org/0000-0001-7311-6790
Jilin University · CN

Funding

Accountant of Jilin Province JLSCZD2019-002Bethune Medical Engineering and Instrument Center #04025290001National Natural Science Foundation of China 81802839National Natural Science Foundation of China 81972669
6 · The paper itself

Abstract

Multiple myeloma (MM) still remains an incurable disease due to widespread drug resistance and high frequency of relapse. In this study, we found that tetrahydrobiopterin (BH4) promotes MM cell proliferation and tumor growth in vivo. BH4 also increases MM bortezomib (Bor) resistance in vitro and in vivo. We show that BH4 increases the expressions of USP7 and USP46 in MM cells, which are responsible for MM Bor resistance primed by BH4. BH4 promotes the degradation of P53 and the activation of NF-κB signaling through the up-regulation of USP7 and USP46. Furthermore, the inhibition of USPs increases the therapeutic effects of Bor in MM tumor bearing mice. Our results demonstrate the important role of BH4 in MM Bor resistance and tumor progression in vivo. These findings could potentially have clinical implications.

Indexed as

AnimalsBiopterinsBortezomibCell Line, TumorDrug Resistance, NeoplasmHumansMiceMice, Inbred BALB CMultiple MyelomaNF-kappa BProteasome InhibitorsSignal TransductionUbiquitin-Specific Peptidase 7BiopterinsBortezomibNF-kappa BProteasome InhibitorssapropterinUbiquitin-Specific Peptidase 7USP7 protein, humanMultiple myelomaNF-κBp53TetrahydrobiopterinUSP7

Identifiers

PMID35150316
PMCPMC8840911
OpenAlexW4211001104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.